Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
X4 Pharmaceuticals, Inc (XFOR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from"
05/04/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update"
03/21/2023 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update"
08/04/2022 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
05/12/2022 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update"
03/17/2022 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update"
11/04/2021 8-K Quarterly results
Docs: "X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data&#59; Company Reports Third Quarter Financial Results"
08/03/2021 8-K Quarterly results
Docs: "X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results"
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
07/30/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2019 X4 PHARMACEUTICALS, INC. Delaware 001-38295 27-3181608 955 Massachusetts Avenue, 4th Floor Cambridge, Massachusetts 02139 529-8300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule ...",
"X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights"
11/09/2018 8-K Quarterly results
Docs: "Arsanis Reports Financial Results for Third Quarter 2018"
08/13/2018 8-K Quarterly results
Docs: "Arsanis Reports Financial Results for Second Quarter 2018"
05/10/2018 8-K Quarterly results
Docs: "Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy